SCNI Scinai Immunotherapeutics Ltd.

NASDAQ
$3.22

Scinai Immunotherapeutics Ltd. (SCNI) Institutional Ownership

What the institutions did with SCNI last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended June 30, 2026.

Managers reporting
11
filed a 13F this quarter
Managers holding
11
+7 on the quarter
Buyers
9
7 opened new
Sellers
1
0 sold out entirely
Buyer share
90.0%
of managers who traded it
Breadth
+80.0
net buyers, as a share of those trading

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
CITADEL ADVISORS LLC 62.3K 32.8%
ARMISTICE CAPITAL, LLC 35.9K 18.9%
Virtu Financial LLC 19.5K 10.3%
XTX Topco Ltd 16.8K 8.8%
RHUMBLINE ADVISERS 13.5K 7.1%
StoneX Group Inc. 13.1K 6.9%
HRT FINANCIAL LP 12.1K 6.4%
CAPTRUST FINANCIAL ADVISORS 12.0K 6.3%
UBS Group AG 4.0K 2.1%
ROYAL BANK OF CANADA 815 0.4%
MORGAN STANLEY 58 0.0%

Largest changes

Manager Action Previous Current Change
CITADEL ADVISORS LLC New 0 62.3K +62.3K
ARMISTICE CAPITAL, LLC New 0 35.9K +35.9K
Virtu Financial LLC New 0 19.5K +19.5K
StoneX Group Inc. New 0 13.1K +13.1K
HRT FINANCIAL LP New 0 12.1K +12.1K
CAPTRUST FINANCIAL ADVISORS New 0 12.0K +12.0K
RHUMBLINE ADVISERS Increased 1.9K 13.5K +11.6K
XTX Topco Ltd Reduced 24.0K 16.8K -7.3K
UBS Group AG Increased 919 4.0K +3.0K
ROYAL BANK OF CANADA New 0 815 +815

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.